Precision Health AI, a healthcare technology company focused on the application of artificial intelligence to cancer care, today announced the launch of the Eureka Health Oncology AI Platform. The 60+ set of pre-trained AI solution modules will utilize Precision Health AI’s proprietary data to predict a patient’s cancer stage, treatment journey, flow through the healthcare system and survival rate.Driving the new Eureka Health Oncology AI platform is Precision Health AI’s deep, longitudinal
Read More
Oncology Technology Solutions, Services Impacting Patients and Providers
Boston Children’s, TriNetX Bring Data-Driven Approach to Clinical Research
Boston Children’s Hospital has joined the TriNetX global health research network to further its efforts at bringing a more data-driven approach to clinical research. The trend in the healthcare industry is to gain access to a wider pool of patient data in an effort to accelerate the study start-up process and identification of patients for clinical trials. Boston Children’s Hospital is live on the network, as of February 1, 2018.TriNetX is the global health research network that enables
Read More
Elsevier Acquires Clinical Decision Support Solution Via Oncology
Elsevier, the information analytics business specializing in science and health, and part of RELX Group, today announced that it has acquired Via Oncology, a Pittsburgh, Pennsylvania-based company that provides clinical decision support and best practices in cancer care management. A former subsidiary of UPMC, one of the nation's leading integrated healthcare delivery and financing systems, Via Oncology helps cancer centers demonstrate the value of their care to patients, referring physicians
Read More
Quest Diagnostics Completes Acquisition of Med Fusion
Quest Diagnostics has announced the completed its acquisition of the laboratory businesses Med Fusion and Clear Point. Operating from a nearly 200,000 square foot facility in Lewisville, Texas, the two businesses form the basis for the company’s first national center of excellence in precision diagnostics for oncology. For patients with cancer, precision diagnostics, such as genomic sequencing of a tumor's DNA, may help a physician select a therapy or clinical trial and monitor response.In
Read More
University of Chicago Medicine, Tempus Partner on Personalized Pancreatic Cancer Project
Pancreatic cancer is the third leading cause of cancer-related death in the United States. It has a five-year survival rate of just nine percent. Lack of effective treatments and early detection methods contribute to this grim prognosis. Personalized approaches to match a patient’s genomic information to therapies have led to improvements in treatment of other cancer types. None of the genetic mutations commonly seen in pancreatic cancer, however, have “druggable” targets.That’s why the
Read More
Penn Medicine’s Abramson Cancer Center Launches Initiative to Improve & Personalize BRCA Mutations
Cancer experts at the Basser Center for BRCA in the Abramson Cancer Center of the University of Pennsylvania have announced a new collaboration with Tempus to improve and personalize treatment for patients with heritable BRCA mutations. Tempus, a technology company focused on helping doctors personalize cancer treatment will analyze the molecular and clinical data of patients who were treated at the Basser Center and harbor a BRCA mutation using machine learning and advanced
Read More
Aurora Cancer Care Launches Precision Medicine Program To Help Patients Gain More Access to Clinical Trials
Aurora Cancer Care, a not-for-profit health care provider in Wisconsin and northern Illinois is launching a precision medicine program powered by Syapse, a provider of precision oncology solutions. The new oncology precision medicine program will help physicians and researchers provide more care options for patients whose cancer is resistant to conventional treatment options like radiation and chemotherapy.The new multi-disciplinary Oncology Precision Medicine Clinic will be located inside
Read More
Researchers Find Most Mobile Health Apps for Cancer Survivors Fail to Deliver Value
Developers of mobile health apps for cancer survivors lack the research needed to determine safety and effectiveness, according to new research conducted at the Cancer Prevention Institute of California (CPIC). The research e-published in the March 24, 2017 issue of the Journal of Cancer Survivorship found basic developmental and incremental testing steps may be skipped in the interest of getting the health app to market quickly.Researchers revealed that most developers only evaluated the app
Read More
Integra Connect Launches First End-to-End Solution for Oncology Care Model Success
Integra Connect, the leading provider of technologies and services for value-based specialty care, today announced a uniquely comprehensive solution for oncology practices participating in the Center for Medicare and Medicaid Services (CMS) Oncology Care Model (OCM) payment program.The OCM, introduced in July of 2016 to further delivery of higher quality, more coordinated oncology care at a lower cost, involves 190 practices representing more than 3,200 US oncologists. Integra Connect’s solution
Read More
GRAIL Lands $900M for Early Cancer Detection
GRAIL, Inc., a life sciences company whose mission is to detect cancer early when it can be cured, today announced it has raised $900 million in Series B funding led by ARCH Venture Partners with participation from Johnson & Johnson Innovation, Amazon, Bristol-Myers Squibb, Celgene, McKesson Ventures, Merck (known as MSD outside the United States and Canada), Tencent Holdings Limited and Varian Medical Systems, Inc. GRAIL intends to close the remainder of the Series B investment prior to the
Read More
